Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644154 | 0.86 | GSTP1 (0.51) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL1375479 | 0.85 | MAPT (0.67) | MAPTLMNANPY1RNPY2RPDE4B | |
| SCHEMBL20279531 | 0.80 | AXL (0.67) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL8800856 | 0.80 | SMN1; SMN2 (0.73) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL3775165 | 0.79 | PDE4B (0.76) | AXLMAPTPDE4BPDE4APDE4C | |
| SCHEMBL13335345 | 0.77 | AXL (0.67) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL11846026 | 0.77 | AXL (0.92) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL5561070 | 0.77 | AXL (0.67) | AXLMAPTLMNANPY1RNPY2R | |
| SCHEMBL5561143 | 0.77 | AXL (0.67) | AXLMAPTLMNAPDE3BPDE3A | |
| SCHEMBL2375581 | 0.76 | AXL (1.00) | AXLMAPTLMNAPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009384-A1 | NOVEL PYRAZOLONE DERIVATIVES AS PD-1/PD-L1 INTERACTION INHIBITORS | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2021-01-21 | — | — | WO | disclosed |
| US-20180170942-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170942-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2016205460-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170942-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | KRAS, HRAS, RALA | AXL 3499/4885MAPT 3522/4885LMNA 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.